AML patient-derived DN T cells target leukemia cells through a perforin-dependent pathway, while healthy donor-derived DN T cells kill leukemia cells partly through IFN-γ, NKG2D and DNAX accessory molecule-1 (DNAM-1). The gene discussed is KLRK1; the disease is acute myeloid leukemia.